INTRODUCTION
Diabetic nephropathy is the most frequent cause for end stage renal disease in the Western world (2) .The incidence of diabetic nephropathy is ~ 40% in type 1 and type 2 diabetic patients (118). Although major risk factors for development and progression of diabetic nephropathy (e.g. poor glycemic control and hypertension) have been identified, diabetic nephropathy can still develop in diabetic patients with well controlled blood glucose concentrations (119). Also, in hypertensive diabetic patients the speed of renal function deterioration can be reduced by appropriate treatment, but treatment as such does not eliminate the susceptibility to develop diabetic nephropathy (120).
A number of epidemiologic studies have suggested that susceptibility to developing diabetic nephropathy is genetically determined (33, 121) . In a linkage analysis performed on 18
Turkish families with type 2 diabetes and nephropathy, we have previously identified a susceptibility locus for diabetic nephropathy on chromosome 18q22.3-q23. Association between diabetic nephropathy and this locus was subsequently confirmed in Pima Indians (40) and African Americans (41). Recently, we have narrowed down this locus and found that susceptibility to develop diabetic nephropathy was related to the presence of a polymorphism in a single gene, the CNDP1 gene (44), encoding for the serum carnosinase protein.
Serum carnosinase, a dipeptidase belonging to the M20 metalloprotease family, is the rate limiting enzyme for the hydrolysis of carnosine and homocarnosine into β-alanine and histidine. Carnosine is an antioxidant (122), inhibits nonenzymatic glycosylation (110), prevents high glucose-induced extracellular matrix accumulation (44) and prevents crosslinking of proteins caused by reactive aldehydes (110). In light of these biochemical properties, it becomes clear that carnosine might be a modulator of hyperglycemia induced damage. Moreover, since carnosine is also a natural ACE inhibitor (114) and since pharmacologic inhibition of the renin-angiotensin-system is known to decline progression of diabetic nephropathy (117, 123), carnosine can be considered a protective factor for diabetic nephropathy. It must be stressed, however, that the findings related to carnosine as an ACE inhibitor must be interpreted with some precaution, as the concentration of carnosine to inhibit ACE is ~ 5.26 mmol/l and thus not in a physiological range (114). Furthermore, although serum carnosine concentrations rapidly increase after ingestion of meat, serum carnosine concentrations are in general very low and decrease after meat ingestion within 5 h to almost undetectable levels (68).
Similar to all secreted proteins, CNDP1 is synthesized as a precursor containing an NH 2 -terminal signal peptide sequence. This enables the nascent protein to be targeted to the endoplasmatic reticulum. In general, signal peptides contain a hydrophobic stretch flanked by polar NH 2 -and COOH-terminal domains (124). The hydrophobic domain is of utmost importance for the function of the signal peptide (125), i.e. for targeting the protein into the secretory pathway. There is a (CTG)n polymorphism (D18S880) located within the signal peptide of the human serum carnosinase. This results in a signal peptide containing a hydrophobic stretch of 4, 5, 6, 7, or 8 leucines (4L-8L alleles). Since diabetic patients homozygous for the 5L allele of CNDP1 are protected from diabetic nephropathy and since serum carnosinase activity is low in these patients, we tested whether carnosinase secretion is determined by the CNDP1 genotype. Another polymorphism within the CNDP1 signal peptide is the arginine to glycine transition in codon 6 (R6G; c.16G>A; rs11151964). The secretion efficiency of this variant, which has not been mentioned in relation to diabetic nephropathy before, was investigated in the present study as well.
RESEARCH DESIGN AND METHODS

Construction of the CNDP1 gene variants
A cDNA clone of the CNDP1 gene (entry no. BX094414, Deutsches Ressourcenzentrum für Genomforschung Library 983) containing six CTG-repeats was kindly provided by Dr. M.
Moeller (Department of Nephrology, Rheinisch-Westfälische Technische Hochschule, Aachen, Germany) and used as a template. In three sequential PCR steps, CNDP1 variants containing 4, 5, 6, 7 or 8 CTG-repeats were constructed. PCRs were performed according to standard methods; sequences of the primers used in each step are depicted in Table 1 . The 6L variant was constructed with either adenine (A) or guanine (G) at position +16. All CNDP1 constructs were cloned into the pCS2 II + MT vector to generate a myc-tagged carnosinase protein. Transformation was performed in competent Escherichia coli (TOP10F'; Invitrogen, Karlsruhe, Germany) using blue-white screening (Sigma, Steinheim, Germany). 
Cell culture and transfection
Cos-7 cells (Invitrogen) were transiently transfected using Nanofectin (PAA Laboratories, Pasching, Austria) as recommended by the manufacturer. Cell supernatants were collected, and cell lysates were prepared 48 h after transfection.
Western blot analysis
Samples were denatured, separated by an 8% SDS-PAGE, and transferred to a polyvinylidine fluoride membrane (Roche, Mannheim, Germany) by means of semidry blotting. 
Statistical analysis
Statistical analysis was performed with SAS software (version 8.02; SAS Institute, Cary, NC).
To investigate the influence of leucine adjusted for time on the percentage of carnosinase, a two-way ANOVA has been used. The difference of secretion efficiency of ≤ 5L to ≥ 6L was shown by planned linear contrasts using the SAS GLM procedure together with contrast statements. Test results with P < 0.05 were considered to be significant.
RESULTS
To test the hypothesis that the length of the hydrophobic leucine stretch in the signal peptide of serum carnosinase influences the efficiency of carnosinase secretion, we constructed myctagged CNDP1 gene variants differing in the number of CTG repeats in the signal sequence.
Constructs encoding 4, 5, 6, 7 or 8 leucines, representing all thus far known alleles for CNDP1, were cloned into Cos-7 cells. In cell extracts of CNDP1 transfected cells, immunereactive bands were detected in Western blot analysis with apparent molecular weights of 86 and 88 kDa respectively. In supernatants of the transfected cells, a single dominant band of ~ 92 kDa was present. Similar data were obtained when monoclonal anti-myc or polyclonal anti-carnosinase antibodies were applied to the Western blot. In cells transfected with the empty vector, no immune-reactive bands were detected (Fig 1) . After PNGase treatment of supernatant and cell extracts, a single band of ~ 86 kDa was found (Fig 2) , suggesting differences in N-glycosylation between both samples.
FIGURE 1
Fig. 1. Western blot analysis of cell protein (C) and supernatant (S) of Cos-7 cells, transfected either with 6L (a) or empty vector (b). Immunostaining with anti-CNPD1 antibody (K18K) and anti-myc antibody is shown.
Immunostaining with anti-CNDP1 of R&D showed similar results (blot not shown). The proportion of carnosinase secreted in the supernatants of all transfectants was assessed by
Western blot and densitometry. In Cos-7 cells expressing CNDP1 containing a 4L or 5L stretch, more carnosinase was found in the cell extracts than in the corresponding supernatants. In contrast, Cos-7 cells expressing gene variants of CNDP1 with more CTG repeats clearly secreted carnosinase much better (Fig.3A) . With increasing length of the CTG repeat the percentage of secreted carnosinase increased (≤5L vs. ≥6L: P<0.0001; Fig. 3B ). In cells transfected with a CNDP1 construct lacking the complete signal peptide, no carnosinase could be detected in supernatants (data not shown). To test if the A to G polymorphism at position +16 (R6G) was also relevant for carnosinase secretion, CNDP1 6L constructs were generated with either adenine or guanine at position +16. No difference in secretion efficiency of carnosinase was found for these variants (6A = 47.4 ± 6.0 and 6G = 46.1 ± 5.2%, P = 0.2707; data not shown). variants was to a similar extent N-glycosylated, as no difference in molecular weight was detected between the variants. The importance of N-glycosylation for secretion efficiency of carnosinase per se was not tested in this study because genetic evidence for the association of serum carnosinase activity and N-glycosylation of carnosinase is lacking. Serum carnosinase deficiency is associated with mental retardation and sensory peripheral neuropathy (128, 129) .
Also, alcoholics with abnormal muscle biopsy findings have low serum carnosinase activity (130); however, it is unclear whether the (CTG)n polymorphism also plays a role in serum carnosinase activity in this group of individuals. In conclusion, we show that the (CTG)n polymorphism in the signal peptide of the CNDP1 gene is functional, determining secretion efficiency of serum carnosinase. Our data also explain why serum carnosinase activity in individuals homozygous for CNDP1 5L is low, resulting in relatively high levels of the renoprotective dipeptide carnosine.
